Truist Financial’s Ascendis Pharma ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$386K Buy
1,696
+105
+7% +$26.6K ﹤0.01% 2358
2026
Q2
$424K Buy
1,591
+327
+26% +$76.4K ﹤0.01% 2312
2026
Q1
$289K Sell
1,264
-525
-29% -$118K ﹤0.01% 2412
2025
Q4
$381K Buy
1,789
+494
+38% +$102K ﹤0.01% 2191
2025
Q3
$257K Buy
+1,295
New +$242K ﹤0.01% 2406
2020
Q3
– Sell
-5
Closed -$1K – 2442
2020
Q2
$1K Buy
+5
New +$686 ﹤0.01% 2400

Other funds holding ASND

Truist Financial's ASND Position: Q3 2026 in Review

Truist Financial increased its Ascendis Pharma (ASND) stake by 6.6% in Q3 2026, buying an estimated $26.6K and bringing the position to 1,696 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #2358.

Truist Financial first reported a position in ASND in Q2 2020 and has held it in 6 quarters since. The position peaked at $424K in Q2 2026. 347 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

  • Truist Financial held 1,696 shares of Ascendis Pharma worth $386K as of Q3 2026.
  • Truist Financial bought 105 Ascendis Pharma shares in Q3 2026, an estimated $26.6K.
  • Ascendis Pharma made up ﹤0.01% of Truist Financial's portfolio in Q3 2026, its #2358 holding.
  • Truist Financial first reported a position in Ascendis Pharma in Q2 2020 and has held it in 6 quarters since.
  • Truist Financial's Ascendis Pharma position peaked at $424K in Q2 2026.
  • 347 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.

Based on Truist Financial's 13F filing for Q3 2026, filed 30 Oct 2026.